ETFs For an Onyx Takeover Battle
July 01, 2013 at 13:02 PM EDT
Mergers and acquisitions activity in the biotechnology sector may have been in a slumber for much of 2013, but that changed last Friday when Onyx Pharmaceuticals (NASDAQ: ONXX ), a maker of cancer treatments, rejected a $120 per share takeover offer from biotech giant Amgen (NASDAQ: AMGN ). That
